Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Multiple Sclerosis Drugs Market Through 2034?

In the past few years, the multiple sclerosis drugs market has witnessed significant growth. The market, with a size of $29.66 billion in 2024, is projected to hit $31.5 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.2%. This growth in the historical period is due to the increasing occurrence of multiple sclerosis, unfulfilled medical requirements, rising investments by pharmaceutical companies, and heightened awareness about multiple sclerosis.

The market for multiple sclerosis medications is predicted to experience accelerated expansions in the upcoming years, with predictions suggesting a size of $47.97 billion by the year 2029 and a compound annual growth rate (CAGR) of 11.1%. The anticipated growth over the forecast period can be traced back to factors such as the heightened presence of clinical trials, targeted therapies, an increased emphasis on preventative medicines, a surge in demand for biosimilars, an extended geographical footprint, and combination therapies. The forecast period is also expected to reveal trends toward immunomodulatory and immunomodulatory drugs, enduring-action formulations, patient-focused care, drug innovation, in addition to oral and infusion therapies.

Which Major Market Drivers Are Expected to Boost the Multiple Sclerosis Drugs Market’s Growth Potential?

The multiple sclerosis drugs market is benefiting from the assistance provided by both government and non-government organisations. Various schemes and programmes, financially supported by these organisations, are in place to improve the quality of life for people suffering from multiple sclerosis (MS). An example of this is the Alberta government’s collaboration with the Department of Economic Development, Trade, and Tourism in Canada, which saw an investment of $1 million into the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This project was created to unify the work of almost 50 MS researchers from different fields throughout Canada. Additional funding was provided for this initiative by Canada Brain Research, Biogen Canada, the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada), accumulating a total of $10 million. This substantial financial backing from both government and non-government organisations is propelling the growth of the multiple sclerosis drugs market.

Request Your Free Multiple Sclerosis Drugs Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Multiple Sclerosis Drugs Market?

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd, EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Which Upcoming Trends Are Set to Influence the Multiple Sclerosis Drugs Market’s Path Forward?

Firms are quickly amplifying their operations to prioritize the introduction of innovative products to meet the escalating demand for MS medications. Given the necessity for continual treatment of multiple sclerosis, it inevitably elevates the comprehensive treatment expenditure for patients. As a solution, corporations in the multiple sclerosis market are in the process of manufacturing medications tailored specifically to the condition. Emergence of this pattern led to FDA’s approval of Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) aimed at addressing relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Both medications were introduced as easily ingestible oral medications.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

What Are the Major Categories and Their Growth Dynamics in the Multiple Sclerosis Drugs Market?

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Subsegments:

1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate

2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab

3) By Interferons: Interferon Beta-1a, Interferon Beta-1b

4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

Which Regions Are Key Players in the Growth of the Multiple Sclerosis Drugs Market?

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

How Is the Scope and Reach of the Multiple Sclerosis Drugs Market Defined?

Multiple Sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as ‘disease-modifying treatment’. These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells’ propensity for nerve injury may be reduced by this impact.

Browse Through More Similar Reports By The Business Research Company:

Central Nervous System Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Neurology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Neuroprosthetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: